LATEST VERIFIED AI EXECUTION
Our quantitative model captured a massive +11.41% net profit on $TIP.MI in just 121h 17m. Stop guessing, start executing.
$1801.HK
INNOVENT BIO
CHINALAST 10 EARNINGS GAPS (%)
QUANTITATIVE LIVE RADAR BLOTTER
Institutional execution stream for $1801.HK
| Execution Date | Strategy & Setup | Direction | Execution Range | Hold Time | Exit Trigger | Net PnL |
|---|---|---|---|---|---|---|
| 2026-08-23 | QUANT ALGO | BUY x5 | $•••.•• → $•••.•• | 40m | 🔒 ENCRYPTED | -8.00% |
| ••••-••-•• | 🔒 LOCKED | ••• x• | $•••.•• → $•••.•• | ••h ••m | 🔒 LOCKED | +••.••% |
| ••••-••-•• | 🔒 LOCKED | ••• x• | $•••.•• → $•••.•• | ••h ••m | 🔒 LOCKED | +••.••% |
Exact execution prices, stop-loss triggers, and full trade logs are reserved for PRO members.
VOLATILITY & BIAS PROFILE
Intelligence Brief
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT… Read full dossier